Publication | Closed Access

Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species

ThrombopoiesisThrombosisPlatelet Aggregation InhibitorsBlood PlateletRepeat Oral DosingPharmacologyPotent AntiplateletPharmacotherapyAntithrombotic ActivityPlatelet AntagonistMedicineAnticoagulantDrug Discovery